Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-10

Study Completion Date

2022-08-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A mild reduction in food intake significantly inhibits renal cyst growth in mouse models of ADPKD. The underlying mechanism was unknown at the time. Recently published data show that the beneficial effect is not due to caloric restriction per se but due to the induction of the state of ketosis. Dietary interventions leading to ketosis profoundly inhibited renal cyst growth in rodent models of PKD. In addition, acute fasting led to rapid regression of renal cystic burden in mouse, rat and feline models of PKD. Due to these compelling effects in a multitude of PKD animal models, and due to the fact that well-established dietary interventions have a tremendous translational potential, KETO-ADPKD will test such interventions regimens in ADPKD patients.

Two well-established ketogenic dietary regimens will be tested in comparison to a control group to address the following four questions:

1. Feasibility: Are ketogenic dietary interventions acceptable to ADPKD patients in everyday life?
2. Safety: Are there adverse events of ketogenic dietary interventions in ADPKD patients?
3. Efficacy: Do the dietary interventions reach the metabolic endpoints? Do they have a short-term impact on kidney volume?
4. Which of the two diets is the optimal approach?

These questions will be addressed in an exploratory, randomized, open, single center, three-arm dietary intervention study using the following interventions in 21 ADPKD patients per treatment arm:

A) Ketogenic diet B) 3-day water fasting C) Control: ad libitum food intake (no diet)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)

NCT01810614

Autosomal Dominant Polycystic Kidney Disease

COMPLETED NA

Di-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT06786260

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NOT_YET_RECRUITING NA

Well-Formulated Ketogenic Diet Polycystic Kidney Disease

NCT06325644

Polycystic Kidney Disease

RECRUITING NA

Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?

NCT06100133

ADPKD

UNKNOWN PHASE2

Renal Protective Effects of Restricted Protein Dietary With α-keto Acid in CAPD Patients

NCT01255020

Renal Function Disorder

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ADPKD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ketogenic diet

Patients will follow a classical ketogenic diet for 3 month

Group Type EXPERIMENTAL

Ketogenic diet

Intervention Type OTHER

Patients will follow a classical ketogenic diet for 3 months

3-days water-fasting

Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months.

Group Type EXPERIMENTAL

3-days water-fasting

Intervention Type OTHER

Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months. In one of the 3 months they are - if required - allowed to split the 3 days into periods of 1 and 2 days. On all other days of the intervention period they are allowed to eat ad libitum.

Control

Patients are allowed to eat ad libitum

Group Type PLACEBO_COMPARATOR

Control

Intervention Type OTHER

Patients are allowed to eat ad libitum, but will be advised that low salt intake (\< 5-7 g/day) and sufficient fluid intake (\>3 l/day) which is considered beneficial in ADPKD.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ketogenic diet

Patients will follow a classical ketogenic diet for 3 months

Intervention Type OTHER

3-days water-fasting

Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months. In one of the 3 months they are - if required - allowed to split the 3 days into periods of 1 and 2 days. On all other days of the intervention period they are allowed to eat ad libitum.

Intervention Type OTHER

Control

Patients are allowed to eat ad libitum, but will be advised that low salt intake (\< 5-7 g/day) and sufficient fluid intake (\>3 l/day) which is considered beneficial in ADPKD.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female ADPKD patients (based on genetics or imaging) ≥ 18 and ≤ 60 years
2. Indicators of rapid progression, either of the following:

* Mayo class 1C-E (measured on screening)
* Truncating PKD1 mutation,
* onset of arterial hypertension/urological symptoms \< 35 years (patient history)
* first- or second degree family members reaching ESRD at \< 60 years of age (patient history),
* eGFR loss \> 2.5 ml/min/yr (as determined by at least 4 serum creatinine values within the last 4 years, with at least 6 months between each measurement ),
* PROPKD score \> 6 (patient history)
3. CKD-stages G1-3 as determined by eGFR (CKD-EPI)
4. Written informed consent

Exclusion Criteria

1. Underweight or obese individuals ( as defined by BMI ≤ 18.5 kg/m2 or ≥ 35 kg/m2)
2. Exposure to a ketogenic diet (classical ketogenic diet or modified Atkins)for more than 2 weeks within the last 6 months
3. Participation in a weight-loss program within the last 6 months based on patient history
4. Vegetarian / vegan lifestyle based on patient history
5. Current treatment (or within the last 6 months) with tolvaptan or a somatostatin analogue based on patient history
6. Inability to give informed consent
7. Conditions prohibiting the use of a ketogenic diet (Liver damage, pancreatic failure, pyruvate-carboxylase deficiency, defects in fatty acid oxidation/gluconeogenesis/ketolysis/-neogenesis, hyperinsulinism) based on patient history
8. Diagnosis with any disorder of fatty acid metabolism including Carnitine deficiency (primary), Carnitine palmitoyltransferase (CPT) I or II deficiency, Carnitine translocase deficiency, Beta-oxidation defects, Medium-chain acyl dehydrogenase deficiency (MCAD), Long-chain acyl dehydrogenase deficiency (LCAD), Short-chain acyl dehydrogenase deficiency (SCAD), Long-chain 3-hydroxyacyl-CoA deficiency, Medium-chain 3-hydroxyacyl-CoA deficiency, Pyruvate carboxylase deficiency based on patient history
9. Eating disorder based on patient history (as defined by the assessment of the study physician)
10. Alcohol abuse based on patient history (as defined by the assessment of the study physician)
11. Type 1 diabetes mellitus based on patient history
12. Insulin-dependent type 2 diabetes mellitus based on patient history
13. Contraindication regarding the MRI exam e.g. non-MRI suitable implants ( including cardiac pacemakers, cochlear implants, aneurysm clip), claustrophobia, large tatoos with metal-containing ink
14. Patients, who may be at risk from the blood loss due to scheduled blood draws at the discretion of the physician
15. Pregnancy or breastfeeding
16. Absence of safe contraceptive measures or non-occurrence of menopause (in women)
17. Participation in other interventional trials
18. Persons who are in a dependency/employment relationship with the investigators
19. Accommodation in an institution by judicial or administrative order.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No